AU2017317129B2 - Entacapone-related compounds to treat macular degeneration - Google Patents

Entacapone-related compounds to treat macular degeneration Download PDF

Info

Publication number
AU2017317129B2
AU2017317129B2 AU2017317129A AU2017317129A AU2017317129B2 AU 2017317129 B2 AU2017317129 B2 AU 2017317129B2 AU 2017317129 A AU2017317129 A AU 2017317129A AU 2017317129 A AU2017317129 A AU 2017317129A AU 2017317129 B2 AU2017317129 B2 AU 2017317129B2
Authority
AU
Australia
Prior art keywords
alkylene
alkyl
formulation
macular degeneration
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017317129A
Other languages
English (en)
Other versions
AU2017317129A1 (en
Inventor
Niu Huang
Shiming PENG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institute of Biological Sciences, Beijing
Original Assignee
National Institute of Biological Sciences, Beijing
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institute of Biological Sciences, Beijing filed Critical National Institute of Biological Sciences, Beijing
Publication of AU2017317129A1 publication Critical patent/AU2017317129A1/en
Application granted granted Critical
Publication of AU2017317129B2 publication Critical patent/AU2017317129B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2017317129A 2016-08-24 2017-08-23 Entacapone-related compounds to treat macular degeneration Active AU2017317129B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016096472 2016-08-24
CNPCT/CN2016/096472 2016-08-24
PCT/CN2017/098575 WO2018036498A1 (en) 2016-08-24 2017-08-23 Entacapone-related compounds to treat macular degeneration

Publications (2)

Publication Number Publication Date
AU2017317129A1 AU2017317129A1 (en) 2019-03-07
AU2017317129B2 true AU2017317129B2 (en) 2020-04-30

Family

ID=61245496

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017317129A Active AU2017317129B2 (en) 2016-08-24 2017-08-23 Entacapone-related compounds to treat macular degeneration

Country Status (7)

Country Link
US (1) US10980766B2 (cg-RX-API-DMAC10.html)
EP (1) EP3503883B1 (cg-RX-API-DMAC10.html)
JP (2) JP6898429B2 (cg-RX-API-DMAC10.html)
CN (1) CN109689042B (cg-RX-API-DMAC10.html)
AU (1) AU2017317129B2 (cg-RX-API-DMAC10.html)
CA (1) CA3034547C (cg-RX-API-DMAC10.html)
WO (1) WO2018036498A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10532976B2 (en) * 2015-06-23 2020-01-14 National Institute Of Biological Sciences, Beijing FTO inhibitors
AU2017317129B2 (en) * 2016-08-24 2020-04-30 National Institute Of Biological Sciences, Beijing Entacapone-related compounds to treat macular degeneration
RS67656B1 (sr) 2018-05-10 2026-02-27 Regeneron Pharma Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
CN116963727A (zh) * 2020-11-13 2023-10-27 普莱克斯医药公司 用于治疗眼部病症的药剂
EP4323329A4 (en) * 2021-04-15 2025-03-05 Brown University Nitrophenyl-acrylamides and uses thereof
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
US20260035341A1 (en) * 2022-07-29 2026-02-05 Rpxds Co., Ltd Fto inhibitors
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
WO2025162358A1 (en) * 2024-01-30 2025-08-07 Rpxds Co., Ltd Fto inhibitors of bicyclic structures
WO2025162373A1 (en) * 2024-01-30 2025-08-07 National Institute Of Biological Sciences, Beijing Electrophile-containing catechol-o-methyltransferase (comt) inhibitors for targeting the keap1/nrf2 pathway

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022140A1 (en) * 2008-08-19 2010-02-25 Knopp Neurosciences, Inc. Compositions and methods of using (r)-pramipexole
US20100190851A1 (en) * 2007-01-17 2010-07-29 Remo Kranich Use of Entacapone in cosmetic, dermatological and pharmaceutical compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI864875A0 (fi) * 1986-11-28 1986-11-28 Orion Yhtymae Oy Nya farmakologiskt aktiva foereningar, dessa innehaollande kompositioner samt foerfarande och mellanprodukter foer anvaendning vid framstaellning av dessa.
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
TW200817315A (en) * 2006-06-16 2008-04-16 Sanol Arznei Schwarz Gmbh Entacapone-derivatives
EP1978014A1 (en) 2007-04-02 2008-10-08 Esteve Quimica, S.A. Process for the preparation of entacapone and intermediates thereof
KR101760139B1 (ko) * 2007-06-29 2017-07-31 클라렌슈 피티와이 리미티드 안투여를 통한 신경 또는 신경정신 장애의 치료 또는 예방용 약학 조성물
BRPI0910575A2 (pt) * 2008-04-18 2017-06-06 Arizona Board Of Regents A Body Corp Of The State Of Arizona Acting For And Behalf Of The Univ Of Ar métodos para tratar degeneração macular relacionada com a idade, para limitar desenvolvimento de degeneração macular relacionada com a idade, e para identificar compostos para tratar degeneração macular relacionada com a idade, e, composição
AR080888A1 (es) * 2010-04-12 2012-05-16 R Tech Ueno Ltd Uso de un derivado de acido graso para producir una composicion oftalmica
WO2012142039A1 (en) * 2011-04-15 2012-10-18 University Of North Dakota Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
CN104869990B (zh) * 2012-10-17 2022-12-20 艾科耐特有限公司 用于治疗眼部新生血管形成的化合物
CN103845317B (zh) 2012-11-28 2018-05-08 北京生命科学研究所 恩他卡朋在预防或治疗肥胖等代谢综合征中的应用
US20160317474A1 (en) * 2013-12-18 2016-11-03 Emory University Managing Visual Dysfunction or Loss of Vision for Diabetic Subjects
CA2975401A1 (en) * 2015-01-30 2016-08-04 Lieber Institute For Brain Development Comt inhibiting methods and compositions
JP6858712B2 (ja) * 2015-01-30 2021-04-14 リーバー インスティテュート フォー ブレイン ディベロップメントＬｉｅｂｅｒ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｒａｉｎ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏｍｔ阻害方法及び組成物
CA2993519C (en) 2015-06-23 2020-03-10 National Institute Of Biological Sciences, Beijing Fto inhibitors
AU2017317129B2 (en) * 2016-08-24 2020-04-30 National Institute Of Biological Sciences, Beijing Entacapone-related compounds to treat macular degeneration

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100190851A1 (en) * 2007-01-17 2010-07-29 Remo Kranich Use of Entacapone in cosmetic, dermatological and pharmaceutical compositions
WO2010022140A1 (en) * 2008-08-19 2010-02-25 Knopp Neurosciences, Inc. Compositions and methods of using (r)-pramipexole

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YONEKAWA, YOSHIHIRO et al., "Clinical Characteristics and Current Treatment of Age- Related Macular Degeneration", COLD SPRING HARB PERSPECTMED, (2014-10-03), vol. 5, no. 1, ISSN 2157-1422 *

Also Published As

Publication number Publication date
JP7116202B2 (ja) 2022-08-09
WO2018036498A1 (en) 2018-03-01
CN109689042B (zh) 2022-07-12
JP6898429B2 (ja) 2021-07-07
CA3034547C (en) 2021-04-13
US20190183842A1 (en) 2019-06-20
CN109689042A (zh) 2019-04-26
EP3503883A1 (en) 2019-07-03
JP2021073265A (ja) 2021-05-13
CA3034547A1 (en) 2018-03-01
JP2019526561A (ja) 2019-09-19
US10980766B2 (en) 2021-04-20
EP3503883B1 (en) 2022-05-04
EP3503883A4 (en) 2020-04-15
AU2017317129A1 (en) 2019-03-07

Similar Documents

Publication Publication Date Title
JP7116202B2 (ja) 黄斑変性症を治療するための医薬の製造におけるエンタカポン関連化合物の使用
WO2018036501A1 (en) Entacapone-related compounds to treat injury
ES2154253T3 (es) Inhibición de la actividad de p38 cinasa usando ureas heterocíclicas sustituidas.
JP5736098B2 (ja) 中枢神経系障害を治療するための医薬組成物
CA3114208A1 (en) Inhibitors of vap-1
RU2496494C2 (ru) КОМБИНАЦИИ, СОДЕРЖАЩИЕ МОДУЛЯТОРЫ mGluR, ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ ПАРКИНСОНА
US20120149706A1 (en) Inhibition of p38 kinase activity using substituted heterocyclic ureas
ES2812800T3 (es) Nuevos usos terapéuticos de derivados de la bencilidenguanidina para el tratamiento de proteopatías
WO2013009810A1 (en) Methods of treatment
EP3790540A1 (en) Methods for treating or limiting development of cardiovascular disease-related neurological disorders
EP3102202A1 (en) Neurodegenerative therapies
CA2872526A1 (en) Dosage regimen for a pi-3 kinase inhibitor
AU2020301057B2 (en) Compounds for treatment of eye disorders
AU2013334860A1 (en) Compositions and methods for treating or preventing diseases or disorders associated with misregulated elF4E
EP4349341A1 (en) Pharmaceutical preparation for preventing or treating pulmonary fibrosis
EA019194B1 (ru) Применение 4-циклопропилметокси-n-(3,5-дихлор-1-оксидопиридин-4-ил)-5-(метокси)пиридин-2-карбоксамида для лечения моторных нарушений, связанных с болезнью паркинсона
KR102159164B1 (ko) 안질환용 치료제
TW201806601A (zh) σ受體配體在皰疹後遺疼痛中的用途
JP7157769B2 (ja) 鎮痛剤化合物
US20140275169A1 (en) Combination Therapies for Enhancing Protein Degradation
CA3244691A1 (en) DUAL LSD1/HDAC INHIBITORS
TH88744A (th) ไบไซคลิคแอริล-ซัลโฟนิคแอซิด[1,3,4]-ไธอะไดแอโซล-2-อิล-แอมีด, กรรมวิธีสำหรับการเตรียมสารเหล่านั้นและการใช้สารเหล่านั้นเป็นสารเภสัชกรรม

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)